Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

S. D. Smith, B. J. Bolwell, L. A. Rybicki, S. Brown, R. Dean, M. Kalaycio, R. Sobecks, S. Andresen, E. D. Hsi, B. Pohlman, J. W. Sweetenham

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.

Original languageEnglish (US)
Pages (from-to)239-243
Number of pages5
JournalBone Marrow Transplantation
Volume40
Issue number3
DOIs
StatePublished - Aug 2007

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen'. Together they form a unique fingerprint.

Cite this